JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 40 No. 5 715-720
© 1999 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, G.-J.
Right arrow Articles by Wong, C. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, G.-J.
Right arrow Articles by Wong, C. T.

Measuring Reproducibility of Regional Brain Metabolic Responses to Lorazepam Using Statistical Parametric Maps

Gene-Jack Wang, Nora D. Volkow, Alejandro V. Levy, Christoph A. Felder, Joanna S. Fowler, Naomi R. Pappas, Robert J. Hitzemann and Christopher T. Wong

Medical and Chemistry Departments, Brookhaven National Laboratory, Upton
Departments of Radiology and Psychiatry, State University of New York, Stony Brook
Psychiatry Service, Veterans Affairs Medical Center, Northport, New York

Correspondence: For correspondence or reprints contact: Gene-Jack Wang, MD, Medical Department, Brookhaven National Laboratory, Upton, NY 11973.

ABSTRACT

Statistical parametric mapping (SPM) is a method for localizing differences in brain activation patterns without the need for anatomic predefined constraints. The purpose of this study was to assess the reproducibility of the patterns of activation obtained with SPM for baseline measures and for metabolic changes in response to lorazepam on a test-retest design. The results were compared with those we previously published using region-of-interest (ROI) methods. Methods: Sixteen healthy right-handed men were scanned twice with PET and [18F]fluorodeoxyglucose (FDG): before placebo and before lorazepam (30 µg/kg). The same double FDG procedure was repeated 6–8 wk later to assess test-retest reproducibility. Image datasets were analyzed by using SPM95 software. Difference images between baseline and lorazepam were compared for the first and second evaluations, both for relative decreases as well as increases in metabolism. Significance level was systematically varied to P < 0.001, P < 0.01 and P < 0.05. Results: There were no differences in the baseline SPM maps obtained for the first and second evaluations. SPM showed similar, although not identical, differences in response to lorazepam between the two evaluations. Both evaluations showed significant decreases in occipital cortex (9.7% and 10%) and significant relative increases in left temporal pole (6.8% and 10.4%). However, the second evaluation showed a decrease in the left frontal cortex (areas 6 and 8), which was not present in the first evaluation. The results were very similar to those we had obtained with ROI methods, except for the activation in the left temporal pole, which we had not observed with ROI analyses. Conclusion: Although the overall pattern of lorazepam-induced activation depicted by SPM was reproducible in pattern and magnitude, there were some differences that included a left frontal area of deactivation during the second but not the first evaluation. Results with SPM are similar to those with the ROI method, and, because it systematically analyses the whole brain, SPM can uncover patterns not seen with the ROI method.

Key Words: benzodiazepines • cerebral glucose metabolism • fluorodeoxyglucose • PET • statistical parametric mapping




This article has been cited by other articles:


Home page
J. Neurosci.Home page
N. D. Volkow, G.-J. Wang, F. Telang, J. S. Fowler, J. Logan, M. Jayne, Y. Ma, K. Pradhan, and C. Wong
Profound Decreases in Dopamine Release in Striatum in Detoxified Alcoholics: Possible Orbitofrontal Involvement
J. Neurosci., November 14, 2007; 27(46): 12700 - 12706.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Azad, S. Pitale, W. E. Barnes, and N. Friedman
Testosterone Treatment Enhances Regional Brain Perfusion in Hypogonadal Men
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3064 - 3068.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Sperling, D. Greve, A. Dale, R. Killiany, J. Holmes, H. D. Rosas, A. Cocchiarella, P. Firth, B. Rosen, S. Lake, et al.
Functional MRI detection of pharmacologically induced memory impairment
PNAS, December 21, 2001; (2001) 12467899.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Sperling, D. Greve, A. Dale, R. Killiany, J. Holmes, H. D. Rosas, A. Cocchiarella, P. Firth, B. Rosen, S. Lake, et al.
Functional MRI detection of pharmacologically induced memory impairment
PNAS, January 8, 2002; 99(1): 455 - 460.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1999 by the Society of Nuclear Medicine.